Abstract
Accurate staging is of importance for taking appropriate management decisions in a patient with newly diagnosed breast cancer. The role of 18FDG-imaging in detecting extra-axillary lymph node involvement and distant lesions in high-risk breast cancer patients is highlighted. This review also discusses potential roles of 18FDG-PET/CT in early assessing response to neoadjuvant chemotherapy. Interim-PET/CT received increased attention in recent years through pilot studies exploring its role in specific subtypes of breast cancer. Results of a French trial that used early metabolic response with 18FDG-PET/CT as a means to select poor responders for intensification have been recently published, with encouraging results.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
